Classificazione della marginalità dei piccoli comuni del Piemonte 2009

Contributi di ricerca ; n.235/2009- Indice #6- Introduzione #8- I piccoli comuni del Piemonte #10- Marginalità socioeconomica #18- I risultati dell'analisi #30- Allegati #4

Classificazione della marginalità dei piccoli comuni del Piemonte 2008

Strumentires ; 12- Indice #3- Introduzione #9- I piccoli comuni del Piemonte #11- La marginalità socioeconomica #16- I risultati dell'analisi #32- Appendici #4

Da margine a centro. Verso un modello di governance per Corona Verde

Da margine a centro. Verso un modello di governance per Corona Verde- Indice #6- Parte 1. Obiettivi e presupposti teorici #12- Parte 2. Le analisi e il confronto con gli stakeholders #26- Parte 3. Dalle analisi ai modelli di governance #50- Parte 4. Le proposte operative #5

Radioresistance in rhabdomyosarcomas: Much more than a question of dose

Management of rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, frequently accounting the genitourinary tract is complex and requires a multimodal therapy. In particular, as a consequence of the advancement in dose conformity technology, radiation therapy (RT) has now become the standard therapeutic option for patients with RMS. In the clinical practice, dose and timing of RT are adjusted on the basis of patients' risk stratification to reduce late toxicity and side effects on normal tissues. However, despite the substantial improvement in cure rates, local failure and recurrence frequently occur. In this review, we summarize the general principles of the treatment of RMS, focusing on RT, and the main molecular pathways and specific proteins involved into radioresistance in RMS tumors. Specifically, we focused on DNA damage/repair, reactive oxygen species, cancer stem cells, and epigenetic modifications that have been reported in the context of RMS neoplasia in both in vitro and in vivo studies. The precise elucidation of the radioresistance-related molecular mechanisms is of pivotal importance to set up new more effective and tolerable combined therapeutic approaches that can radiosensitize cancer cells to finally ameliorate the overall survival of patients with RMS, especially for the most aggressive subtypes

Cinque anni insieme

Il contributo, che costituisce l'editoriale della rivista EyesReg per l'anno 2016, riepiloga i temi più interessanti e gli elementi più significativi dell'attività della rivista nel corso dell'ultimo ann

MS-275 (Entinostat) Promotes Radio-sensitivity in PAX3-FOXO1 Rhabdomyosarcoma cells

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. About 25% of RMS expresses fusion oncoproteins such as PAX3/PAX7‐FOXO1 (fusion‐positive, FP) while fusion‐negative (FN)‐RMS harbors RAS mutations. Radiotherapy (RT) plays a crucial role in local control but metastatic RMS is often radio‐resistant. HDAC inhibitors (HDACi) radio‐sensitize different cancer cells types. Thus, we evaluated MS−275 (Entinostat), a Class I and IV HDACi, in combination with RT on RMS cells in vitro and in vivo. MS−275 reversibly hampered cell survival in vitro in FN‐RMS RD (RASmut) and irreversibly in FP‐RMS RH30 cell lines down‐regulating cyclin A, B, and D1, up‐regulating p21 and p27 and reducing ERKs activity, and c‐Myc expression in RD and PI3K/Akt/mTOR activity and N‐Myc expression in RH30 cells. Further, MS−275 and RT combination reduced colony formation ability of RH30 cells. In both cell lines, co‐treatment increased DNA damage repair inhibition and reactive oxygen species formation, down‐regulated NRF2, SOD, CAT and GPx4 anti‐oxidant genes and improved RT ability to induce G2 growth arrest. MS−275 inhibited in vivo growth of RH30 cells and completely prevented the growth of RT‐unresponsive RH30 xenografts when combined with radiation. Thus, MS−275 could be considered as a radio‐sensitizing agent for the treatment of intrinsically radio‐resistant PAX3‐FOXO1 RMS

Rapporto di quadrante. Il sud-ovest

Rapporto di quadrante. Il sud-ovest- Indice #